Nanobiotix (NBTX) Current Deferred Revenue (2021 - 2025)

Nanobiotix (NBTX) has 5 years of Current Deferred Revenue data on file, last reported at $42.1 million in Q4 2025.

• In Q4 2025, Current Deferred Revenue rose 117.86% year-over-year to $42.1 million; the TTM figure through Dec 2025 stood at $42.1 million (up 117.86% YoY), while the FY2025 annual figure was $40.9 million, up 108.77% from the prior year.
• Current Deferred Revenue grew to $42.1 million in Q4 2025, from $19.3 million in the prior quarter.
• Across five years, Current Deferred Revenue topped out at $42.1 million in Q4 2025 and bottomed at $16.9 million in Q4 2022.
• A 5-year average of $23.3 million and a median of $19.3 million in 2024 frame the typical range for Current Deferred Revenue.
• Annual changes were most pronounced in 2022 — Current Deferred Revenue declined 10.72% — and 2025, when it surged 117.86%.
• Year by year, Current Deferred Revenue stood at $18.9 million in 2021, then decreased by 10.72% to $16.9 million in 2022, then grew by 15.56% to $19.5 million in 2023, then fell by 0.68% to $19.3 million in 2024, then surged by 117.86% to $42.1 million in 2025.
• The last three Current Deferred Revenue figures came in at $42.1 million (Q4 2025), $19.3 million (Q4 2024), and $19.5 million (Q4 2023), per Business Quant data.

Peer Comparison